Tag: Emmanuelle Charpentier

February 21, 2017

Thom Calandra: Investing in Gene-editing Stocks

Thom Calandra is known to investors in the resource space. Recently, he wrote about biotechnology and started his own index...
February 15, 2017

The CRISPR-Cas9 Patent Dispute

The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
February 15, 2017

Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference

Editas Medicine (NASDAQ:EDIT) reported that the US Patent and Trademark Office has issued a favorable decision in the CRISPR interference...
December 16, 2016

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a...
March 10, 2016

After Hot IPO Editas Medicine Bogged Down by CRISPR/Cas9 Legal Issues

Editas Medicine's share price went on a tear following its IPO in February. In the last two days, however, it's...